Industrial Breakthrough in Starch Blocking: 90% α-Amylase Inhibition Rate with Unprecedented Stability

Meta Description

Clinically proven white kidney bean extract(Phaseolus vulgaris) delivering 90% α-amylase inhibition. Blue Eyes Biotech’spatented stabilization technology ensures year-long efficacy. Request samplesfor nutraceutical, cosmetic & pharmaceutical applications.

Technical Abstract

Blue Eyes Biotech announces anindustrial-scale breakthrough in standardized white kidney bean extract (PatentNo.: BE2024-WKBE) achieving consistent 90% α-amylase inhibition – the highestclinically validated activity for carbohydrate management. Our proprietary**cold-phase enzymatic extraction** eliminates thermal degradation, resolvingthe industry-wide stability crisis where traditional extracts lose >40% potencywithin 3 months. Third-party accelerated studies confirm **>95% retention ofactive phaseolamin after 12 months at 25°C/60% RH, outperforming competitors by3-fold stability.  

Cost-efficiency is engineered at molecularlevel: novel affinity chromatography purification reduces production waste by62%, enabling bulk ODM pricing below $85/kg for 15-ton batches (MOQ 500kg).Cross-industry applications include: 1) **Nutraceuticals – enteric-coatedcapsules with 89% inhibition in human trials (n=120); 2) Functional Foods–heat-resistant powder stable in baking up to 180°C; 3) Cosmeceuticals– inhibitsglycation-induced skin aging (in vitro BSA-glycation modelIC50=0.22mg/ml).  

Compliance is guaranteed with dual FDA GRAS(No. 1287) and ISO 22000 certification, while non-GMO verification meets EUNovel Food requirements. For procurement teams, we offer:  

Free 2kg samples** with inhibition assayreports  

Customized dossier** including HPLC-ELSDquantification protocols  

Scale-up support** from R&D tocommercial batches  

Request Technical Package:[email protected]   www.blueeyes-bio.com